Bill
S 2398
Reauthorizes and extends federal funds and coordination for tick- and vector-borne disease programs through 2030.
Below is a clear, objective summary of the materials you provided. The documents attached to “S 2398” appear to include two different bills from different jurisdictions plus an initial title that does not match the bill texts. I summarize each distinct item present and note the inconsistency.
Summary — key point about inconsistency
- The supplied packet contains: (A) a U.S. Senate bill (S. 2398, 119th Congress) titled the “Kay Hagan Tick Reauthorization Act”; (B) a Massachusetts Senate bill (Senate No. 2398 / Docket No. 871) directing the MBTA to place naloxone in subway stations; and (C) an initial one‑line title about genetic testing privacy that is not reflected in the bill texts provided. I summarize (A) and (B) below and note that the genetic‑testing title appears not to correspond to any included bill text.
A. U.S. Senate — S. 2398 (119th Congress): “Kay Hagan Tick Reauthorization Act”
Purpose and intent
- Reauthorize and extend federal programs addressing tick‑borne and other vector‑borne diseases established under the Public Health Service Act, continuing federal coordination, strategy and regional center support.
Key provisions / changes
- Amends Section 317U of the Public Health Service Act (42 U.S.C. 247b–23):
- Edits language in subsection (b) to replace a specific cross‑reference (the Tick‑Borne Disease Working Group established under the 21st Century Cures Act) with more general “appropriate individuals.”
- Extends the authorization period in subsection (f) from “2021 through 2025” to “2026 through 2030.”
- Amends Section 2822(c) (42 U.S.C. 300hh–32(c)) to extend program authorization and support for health departments addressing vector‑borne diseases from “2021 through 2025” to “2026 through 2030.”
Who is affected
- Federal public health agencies (e.g., HHS/CDC) that administer national strategy and regional center grants and programs for vector‑borne disease surveillance, research and response.
- State and local health departments that receive enhanced support/grants to address vector‑borne diseases.
- Researchers, regional centers of excellence, and stakeholders in tick‑borne disease prevention and response.
Procedural / timeline notes (from supplied record)
- Introduced July 23, 2025 (by Senator Susan M. Collins with multiple cosponsors).
- Referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP).
- Committee actions reported (amendment in the nature of a substitute), placed on Senate Legislative Calendar (Calendar No. 154), hearing scheduled (10/07/2025 per the record).
- Companion bills noted (e.g., H.R. 4348, S. 2294).
B. Massachusetts — Senate No. 2398 / Docket No. 871: “An Act directing the Massachusetts Bay Transportation Authority to place naloxone in subway stations”
Purpose and intent
- Make opioid overdose reversal medication (naloxone) publicly accessible in MBTA subway stations to reduce fatalities from opioid overdoses and improve emergency response.
Key provisions
- Requires the Massachusetts Bay Transportation Authority (MBTA) to place accessible naloxone at all MBTA Blue, Green, Orange and Red Line stations.
- Each station must have two freestanding unalarmed naloxone boxes; each box to contain two units of 4 mg intranasal naloxone spray.
- Boxes must be checked daily and restocked if used.
- Flyers describing naloxone training and instructions for emergency use must be posted near boxes.
- MBTA must report on the program’s efficacy to legislative clerks and the joint committee on mental health, substance use and recovery. The report must include benefits, costs and recommendations for improvement/expansion and be filed not sooner than 12 months and not later than 18 months after program start.
Who is affected
- MBTA riders and staff, especially those at risk of or encountering opioid overdoses.
- MBTA operations and maintenance staff (daily box checks and restocking).
- State public health and legislative oversight bodies that will receive evaluation reports.
Procedural / timeline notes (from supplied record)
- Filed in the Massachusetts Senate January 15, 2025 (sponsored by Sen. John F. Keenan, with other petitioners).
- Passed the Massachusetts Senate (record shows May 29, 2025) and was delivered to the Assembly; subsequently referred to the Assembly’s Governmental Operations committee. Additional internal committee references (Transport, Codes) appear in the record.
Notes on the initial “genetic testing” title
- The header line you supplied (“Requires genetic testing results only be received by patients and health care providers providing direct care while health insurance companies only receive a record that the genetic testing was performed”) is not represented in the full texts you attached. No statutory language, section references, or bill text in the packet implements that policy. If you intended to summarize a genetic‑testing privacy bill, please provide the actual bill text or citation so I can prepare an accurate summary.
If you want, I can:
- Produce a standalone one‑page fact sheet for either the federal reauthorization bill or the Massachusetts naloxone bill; or
- Draft a comparison of both bills’ potential public‑health impacts; or
- Summarize or draft the missing genetic‑testing bill if you supply its text.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
